Market Cap | 3.48B | P/E | - | EPS this Y | 12.70% | Ern Qtrly Grth | - |
Income | -519.21M | Forward P/E | -10.18 | EPS next Y | -13.10% | 50D Avg Chg | 25.00% |
Sales | 742k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 36.00% |
Dividend | N/A | Price/Book | 3.66 | EPS next 5Y | - | 52W High Chg | - |
Recommedations | 1.50 | Quick Ratio | 15.10 | Shares Outstanding | 167.04M | 52W Low Chg | 92.00% |
Insider Own | 2.14% | ROA | -24.95% | Shares Float | 153.31M | Beta | 1.43 |
Inst Own | 104.25% | ROE | -40.73% | Shares Shorted/Prior | 17.17M/16.84M | Price | 32.78 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,021,824 | Target Price | 60.08 |
Oper. Margin | -77,524.66% | Earnings Date | Nov 4 | Volume | 3,063,320 | Change | 4.06% |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Barclays | Overweight | Sep 27, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
JP Morgan | Overweight | Aug 8, 24 |
Wedbush | Outperform | Aug 8, 24 |
Needham | Buy | Aug 8, 24 |
Barclays | Overweight | Jul 18, 24 |
Oppenheimer | Outperform | Jul 16, 24 |
B of A Securities | Buy | Jul 16, 24 |
HC Wainwright & Co. | Buy | Jul 16, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Sell | 25.9018 | 1,775 | 45,976 | 76,416 | 12/20/23 |
GOLDSMITH MARK A | See Remarks See Remarks | Dec 18 | Sell | 25.9018 | 8,165 | 211,488 | 376,167 | 12/20/23 |
Cislini Jeff | General Counsel General Counsel | Dec 18 | Sell | 25.9017 | 1,229 | 31,833 | 37,284 | 12/20/23 |
Kelsey Stephen Michael | See Remarks See Remarks | Dec 18 | Sell | 25.9016 | 2,088 | 54,083 | 271,633 | 12/20/23 |
Horn Margaret A | Chief Operating Offi.. Chief Operating Officer | Dec 15 | Sell | 26.27 | 7,993 | 209,976 | 101,467 | 12/19/23 |
Horn Margaret A | Chief Operating Offi.. Chief Operating Officer | Dec 15 | Option | 4.09 | 5,000 | 20,450 | 109,460 | 12/19/23 |
Cislini Jeff | General Counsel General Counsel | Nov 20 | Sell | 21.6966 | 1,500 | 32,545 | 38,513 | 11/20/23 |
Horn Margaret A | Chief Operating Offi.. Chief Operating Officer | Oct 25 | Option | 0.54 | 7,500 | 4,050 | 104,460 | 10/25/23 |
GOLDSMITH MARK A | See Remarks See Remarks | Oct 24 | Option | 0.49 | 35,000 | 17,150 | 384,332 | 10/24/23 |
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Oct 23 | Option | 3.39 | 24,524 | 83,136 | 78,191 | 10/23/23 |
Cislini Jeff | General Counsel General Counsel | Sep 28 | Sell | 28.58 | 2,000 | 57,160 | 40,013 | 10/02/23 |
GOLDSMITH MARK A | See Remarks See Remarks | Sep 01 | Option | 0.83 | 30,000 | 24,900 | 387,386 | 09/06/23 |
GOLDSMITH MARK A | See Remarks See Remarks | Sep 01 | Sell | 35.04 | 40,000 | 1,401,600 | 35,424 | 09/06/23 |
Weber Barbara | Director Director | Sep 01 | Sell | 35.07 | 15,000 | 526,050 | 15,825 | 09/06/23 |
Weber Barbara | Director Director | Sep 01 | Option | 2.93 | 15,000 | 43,950 | 30,825 | 09/06/23 |
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Sep 01 | Sell | 35.05 | 20,000 | 701,000 | 55,094 | 09/06/23 |
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Sep 01 | Option | 2.68 | 20,000 | 53,600 | 75,094 | 09/06/23 |
Cislini Jeff | General Counsel General Counsel | Jul 31 | Sell | 26.02 | 1,500 | 39,030 | 43,227 | 08/01/23 |
Horn Margaret A | See Remarks See Remarks | Mar 17 | Sell | 21.78 | 1,230 | 26,789 | 100,062 | 03/21/23 |
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Mar 17 | Sell | 21.78 | 665 | 14,484 | 55,233 | 03/21/23 |
Kelsey Stephen Michael | See Remarks See Remarks | Mar 17 | Sell | 21.78 | 1,230 | 26,789 | 326,369 | 03/21/23 |
Wang Xiaolin | See Remarks See Remarks | Mar 17 | Sell | 21.78 | 714 | 15,551 | 58,813 | 03/21/23 |
Schroeder Thilo | Director Director | Mar 07 | Buy | 21.32 | 650,000 | 13,858,000 | 1,553,134 | 03/10/23 |
GOLDSMITH MARK A | See Remarks See Remarks | Feb 22 | Option | 0.49 | 45,000 | 22,050 | 251,872 | 02/23/23 |
Horn Margaret A | Chief Operating Offi.. Chief Operating Officer | Oct 31 | Sell | 20.4053 | 17,767 | 362,541 | 17,767 | 11/02/22 |
Wang Xiaolin | See Remarks See Remarks | Sep 19 | Sell | 19.0426 | 735 | 13,996 | 31,235 | 09/21/22 |
Kelsey Stephen Michael | See Remarks See Remarks | Sep 19 | Sell | 19.0426 | 1,267 | 24,127 | 288,819 | 09/21/22 |
Horn Margaret A | See Remarks See Remarks | Sep 19 | Sell | 19.0426 | 1,267 | 24,127 | 62,512 | 09/21/22 |
Anders Jack | Chief Financial Offi.. Chief Financial Officer | Sep 19 | Sell | 19.0426 | 449 | 8,550 | 29,956 | 09/21/22 |
GOLDSMITH MARK A | See Remarks See Remarks | Aug 11 | Option | 0.49 | 10,000 | 4,900 | 206,872 | 08/15/22 |
GOLDSMITH MARK A | See Remarks See Remarks | Aug 09 | Option | 0.49 | 10,336 | 5,065 | 196,872 | 08/10/22 |
Schroeder Thilo | Director Director | Jul 22 | Buy | 20.00 | 250,000 | 5,000,000 | 1,221,315 | 07/26/22 |
Kim Lorence H. | Director Director | Jul 22 | Buy | 20.00 | 50,000 | 1,000,000 | 60,500 | 07/25/22 |
Wang Xiaolin | See Remarks See Remarks | Jun 17 | Sell | 17.7495 | 665 | 11,803 | 31,970 | 06/22/22 |
Kelsey Stephen Michael | See Remarks See Remarks | Jun 17 | Sell | 17.7495 | 1,145 | 20,323 | 290,086 | 06/22/22 |
Horn Margaret A | See Remarks See Remarks | Jun 17 | Sell | 17.7495 | 1,145 | 20,323 | 63,779 | 06/22/22 |
Anders Jack | See Remarks See Remarks | Jun 17 | Sell | 17.7495 | 406 | 7,206 | 20,405 | 06/22/22 |
Third Rock Ventures III, L.P. | 10% Owner 10% Owner | Jun 08 | Sell | 20.25 | 419,901 | 8,502,995 | 5,104,130 | 06/10/22 |
Exter Neil | Director Director | Jun 08 | Sell | 0.00 | 06/10/22 | |||
Schroeder Thilo | Director Director | Mar 25 | Buy | 24.85 | 42,725 | 1,061,716 | 971,315 | 03/29/22 |
Schroeder Thilo | Director Director | Mar 22 | Buy | 23.48 | 232,364 | 5,455,907 | 928,590 | 03/24/22 |
Schroeder Thilo | Director Director | Mar 17 | Buy | 20.08 | 168,051 | 3,374,464 | 696,226 | 03/21/22 |
Horn Margaret A | See Remarks See Remarks | Mar 17 | Sell | 18.6145 | 321 | 5,975 | 63,987 | 03/21/22 |
Kelsey Stephen Michael | See Remarks See Remarks | Mar 17 | Sell | 18.6162 | 321 | 5,976 | 290,294 | 03/21/22 |
Wang Xiaolin | See Remarks See Remarks | Mar 17 | Sell | 18.6142 | 240 | 4,467 | 31,698 | 03/21/22 |
GOLDSMITH MARK A | See Remarks See Remarks | Mar 17 | Sell | 18.6141 | 1,023 | 19,042 | 185,599 | 03/21/22 |
Anders Jack | See Remarks See Remarks | Mar 17 | Sell | 18.6162 | 159 | 2,960 | 19,875 | 03/21/22 |
Schroeder Thilo | Director Director | Mar 10 | Buy | 20.91 | 43,510 | 909,794 | 528,175 | 03/14/22 |
Schroeder Thilo | Director Director | Mar 07 | Buy | 19.14 | 246,438 | 4,716,823 | 484,665 | 03/09/22 |
Schroeder Thilo | Director Director | Feb 18 | Buy | 23.17 | 1,088,227 | 25,214,220 | 238,227 | 03/04/22 |